articleThe LancetJun 12, 2013Closed access

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

IBIain B. McInnesAKArthur KavanaughABAlice B. GottliebLPL. PuigPRProton Rahman

University of Glasgow · University of California, San Diego · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

795
total citations
FWCI
64.47
Percentile
100%
References
47
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Ustekinumab
  • Psoriatic arthritis
  • Medicine
  • Placebo
  • Double blind
  • Internal medicine
  • Arthritis
  • Dermatology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding